Zimmer Biomet Holdings, Inc. (NYSE:ZBH) updated its fourth quarter earnings guidance on Wednesday. The company provided EPS guidance of $2.08-$2.14 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.27. The company issued revenue guidance of $2.01-$2.05 billion, compared to the consensus revenue estimate of $2.07 billion.Zimmer Biomet Holdings also updated its FY17 guidance to $8.01-$8.07 EPS.
A number of research analysts have issued reports on the stock. Morgan Stanley upped their target price on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an overweight rating in a research report on Monday, July 17th. Piper Jaffray Companies restated a buy rating and set a $141.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Stifel Nicolaus restated a hold rating and set a $125.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Bank of America Corporation reaffirmed a buy rating and issued a $158.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Finally, Wells Fargo & Company reaffirmed a market weight rating on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Zimmer Biomet Holdings has a consensus rating of Hold and an average price target of $135.00.
Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter last year, the company posted $1.79 EPS. The company’s quarterly revenue was down .8% compared to the same quarter last year.
The business also recently declared a quarterly dividend, which was paid on Friday, October 27th. Investors of record on Friday, September 22nd were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, September 21st. This represents a $0.96 annualized dividend and a yield of Infinity. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is currently 30.19%.
ILLEGAL ACTIVITY NOTICE: This story was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.com-unik.info/2017/11/03/zimmer-biomet-holdings-inc-zbh-issues-q4-earnings-guidance.html.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.